33.99
-1.07(-3.05%)
Currency In USD
| Previous Close | 35.06 |
| Open | 35.66 |
| Day High | 36.03 |
| Day Low | 32.78 |
| 52-Week High | 60.37 |
| 52-Week Low | 29.59 |
| Volume | 854,857 |
| Average Volume | 852,318 |
| Market Cap | 3.19B |
| PE | -5.4 |
| EPS | -6.29 |
| Moving Average 50 Days | 37.66 |
| Moving Average 200 Days | 46.35 |
| Change | -1.07 |
If you invested $1000 in Ultragenyx Pharmaceutical Inc. (RARE) 10 years ago, it would be worth $549.11 as of May 07, 2025 at a share price of $33.99. Whereas If you bought $1000 worth of Ultragenyx Pharmaceutical Inc. (RARE) shares 5 years ago, it would be worth $538.5 as of May 07, 2025 at a share price of $33.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update
GlobeNewswire Inc.
Apr 30, 2025 9:00 PM GMT
NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today
Ultragenyx to Participate at Investor Conferences in March
GlobeNewswire Inc.
Feb 24, 2025 9:30 PM GMT
NOVATO, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today
Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
GlobeNewswire Inc.
Feb 18, 2025 1:00 PM GMT
FDA decision expected by August 18, 2025NOVATO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted for review the Biologics